Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA granted fast track designation to phentolamine ophthalmic solution 0.75% to treat significant chronic night driving impairment in patients who have undergone keratorefractive surgery.
According to a press release from Opus Genetics, the designation will expedite the development and review of phentolamine in patients with reduced mesopic vision and photic phenomena.
“This designation offers Opus Genetics several key benefits, including more frequent interactions with the FDA, eligibility for